Cholangiocarcinoma 2020: the next horizon in mechanisms and management

JM Banales, JJG Marin, A Lamarca… - Nature reviews …, 2020 - nature.com
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant
tumours that can arise at any point of the biliary tree. Their incidence is increasing globally …

Gallbladder cancer

JC Roa, P García, VK Kapoor, SK Maithel… - Nature reviews Disease …, 2022 - nature.com
Gallbladder cancer (GBC) is the most common cancer of the biliary tract, characterized by a
very poor prognosis when diagnosed at advanced stages owing to its aggressive behaviour …

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single …

DY Oh, KH Lee, DW Lee, J Yoon, TY Kim… - The lancet …, 2022 - thelancet.com
Background Immunotherapies have shown clinical activity in patients with advanced biliary
tract cancer, for which outcomes remain poor despite standard of care treatment with …

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

A Lamarca, DH Palmer, HS Wasan, PJ Ross… - The Lancet …, 2021 - thelancet.com
Background Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine
is the standard first-line chemotherapy regimen, but no robust evidence is available for …

[HTML][HTML] Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

L Izquierdo-Sanchez, A Lamarca, A La Casta… - Journal of …, 2022 - Elsevier
Background & Aims Cholangiocarcinoma (CCA) is a rare and heterogeneous biliary cancer,
whose incidence and related mortality is increasing. This study investigates the clinical …

Burden of liver diseases in the world

SK Asrani, H Devarbhavi, J Eaton, PS Kamath - Journal of hepatology, 2019 - Elsevier
Liver disease accounts for approximately 2 million deaths per year worldwide, 1 million due
to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular …

Molecular targeted therapies: ready for “prime time” in biliary tract cancer

A Lamarca, J Barriuso, MG McNamara, JW Valle - Journal of hepatology, 2020 - Elsevier
The prognosis for patients with biliary tract cancers (cholangiocarcinoma and gallbladder
cancer) is poor, while the incidence of these cancers is increasing. Most patients are …

Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline

RT Shroff, EB Kennedy, M Bachini… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical
decision making for patients with resected biliary tract cancer. METHODS ASCO convened …

[HTML][HTML] Clinical treatment of cholangiocarcinoma: an updated comprehensive review

A Elvevi, A Laffusa, M Scaravaglio, RE Rossi… - Annals of …, 2022 - Elsevier
Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms of the bile ducts and
represents the second most common hepatic cancer after hepatocellular carcinoma; it is sub …

[HTML][HTML] Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

A Lapitz, M Azkargorta, P Milkiewicz, P Olaizola… - Journal of …, 2023 - Elsevier
Background & Aims Cholangiocarcinoma (CCA), heterogeneous biliary tumours with dismal
prognosis, lacks accurate early diagnostic methods especially important for individuals at …